OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
Julius Hollnberger, Yang Liu, Simin Xu, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 657-665
Closed Access | Times Cited: 18
Julius Hollnberger, Yang Liu, Simin Xu, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 657-665
Closed Access | Times Cited: 18
Showing 18 citing articles:
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Tarik Asselah, Vladimir Chulanov, Pietro Lampertico, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 133-143
Closed Access | Times Cited: 23
Tarik Asselah, Vladimir Chulanov, Pietro Lampertico, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 133-143
Closed Access | Times Cited: 23
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies
Lena Allweiss, Annika Volmari, Vithika Suri, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 882-891
Open Access | Times Cited: 18
Lena Allweiss, Annika Volmari, Vithika Suri, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 882-891
Open Access | Times Cited: 18
Structural basis of hepatitis B virus receptor binding
Jinta Asami, Jae-Hyun Park, Yayoi Nomura, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 3, pp. 447-454
Closed Access | Times Cited: 16
Jinta Asami, Jae-Hyun Park, Yayoi Nomura, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 3, pp. 447-454
Closed Access | Times Cited: 16
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 621-629
Open Access | Times Cited: 13
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 621-629
Open Access | Times Cited: 13
Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients
Verdiana Zulian, Leonidas Salichos, Chiara Taibi, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 280-280
Open Access
Verdiana Zulian, Leonidas Salichos, Chiara Taibi, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 280-280
Open Access
Current and future therapeutic options for chronic hepatitis D virus infection
Mariantonietta Pisaturo, Giovanna Russo, Pierantonio Grimaldi, et al.
Frontiers in Cellular and Infection Microbiology (2025) Vol. 14
Open Access
Mariantonietta Pisaturo, Giovanna Russo, Pierantonio Grimaldi, et al.
Frontiers in Cellular and Infection Microbiology (2025) Vol. 14
Open Access
Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study
Magdalena Meszaros, Marie‐Noëlle Hilleret, Jérôme Dumortier, et al.
Liver International (2025) Vol. 45, Iss. 3
Open Access
Magdalena Meszaros, Marie‐Noëlle Hilleret, Jérôme Dumortier, et al.
Liver International (2025) Vol. 45, Iss. 3
Open Access
Reassessing the Safety of Bulevirtide in Chronic Hepatitis Delta: A Critical Perspective
Tarik Asselah, Renée-Claude Mercier, Dmitry Manuilov, et al.
Liver International (2025) Vol. 45, Iss. 5
Closed Access
Tarik Asselah, Renée-Claude Mercier, Dmitry Manuilov, et al.
Liver International (2025) Vol. 45, Iss. 5
Closed Access
Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field
Sheila Lumley, Jolynne Mokaya, Tongai Maponga, et al.
The Lancet Microbe (2025), pp. 101076-101076
Open Access
Sheila Lumley, Jolynne Mokaya, Tongai Maponga, et al.
The Lancet Microbe (2025), pp. 101076-101076
Open Access
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide
Pierluigi Toniutto, Edmondo Falleti, Sara Cmet, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 5, pp. 819-826
Closed Access | Times Cited: 3
Pierluigi Toniutto, Edmondo Falleti, Sara Cmet, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 5, pp. 819-826
Closed Access | Times Cited: 3
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48
Tarik Asselah, Pietro Lampertico, Soo Aleman, et al.
Liver International (2024)
Open Access | Times Cited: 2
Tarik Asselah, Pietro Lampertico, Soo Aleman, et al.
Liver International (2024)
Open Access | Times Cited: 2
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies
Pietro Lampertico, Maria Paola Anolli, Dominique Roulot, et al.
Gut (2024), pp. gutjnl-332597
Closed Access | Times Cited: 2
Pietro Lampertico, Maria Paola Anolli, Dominique Roulot, et al.
Gut (2024), pp. gutjnl-332597
Closed Access | Times Cited: 2
Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations
Louis Shekhtman, Scott J. Cotler, Elisabetta Degasperi, et al.
JHEP Reports (2023) Vol. 6, Iss. 2, pp. 100966-100966
Open Access | Times Cited: 6
Louis Shekhtman, Scott J. Cotler, Elisabetta Degasperi, et al.
JHEP Reports (2023) Vol. 6, Iss. 2, pp. 100966-100966
Open Access | Times Cited: 6
Virological markers for clinical trials in chronic viral hepatitis
Jean‐Michel Pawlotsky
JHEP Reports (2024) Vol. 6, Iss. 11, pp. 101214-101214
Open Access | Times Cited: 1
Jean‐Michel Pawlotsky
JHEP Reports (2024) Vol. 6, Iss. 11, pp. 101214-101214
Open Access | Times Cited: 1
Advances in hepatitis delta research: emerging insights and future directions
Elisabetta Degasperi, Maria Paola Anolli, Pietro Lampertico
Sexually Transmitted Infections (2024) Vol. 100, Iss. 5, pp. 310-317
Closed Access
Elisabetta Degasperi, Maria Paola Anolli, Pietro Lampertico
Sexually Transmitted Infections (2024) Vol. 100, Iss. 5, pp. 310-317
Closed Access
Chronic Hepatitis D Virus Infection and Its Treatment: A Narrative Review
Poonam Mathur, Arshi Khanam, Shyam Kottilil
Microorganisms (2024) Vol. 12, Iss. 11, pp. 2177-2177
Open Access
Poonam Mathur, Arshi Khanam, Shyam Kottilil
Microorganisms (2024) Vol. 12, Iss. 11, pp. 2177-2177
Open Access
Hepatitis B and D virus entry
Koichi Watashi, Kaho Shionoya, Chisa Kobayashi, et al.
Nature Reviews Microbiology (2024)
Closed Access
Koichi Watashi, Kaho Shionoya, Chisa Kobayashi, et al.
Nature Reviews Microbiology (2024)
Closed Access
Hepatitis Delta: Ready for primetime?
Benjamin Maasoumy, Pietro Lampertico
Liver International (2023) Vol. 43, Iss. S1, pp. 1-4
Open Access
Benjamin Maasoumy, Pietro Lampertico
Liver International (2023) Vol. 43, Iss. S1, pp. 1-4
Open Access
